All News
Filter News
Found 93 articles
-
Pharvaris Highlights Data Supporting Clinical Development Program for Hereditary Angioedema at the 2022 Bradykinin Symposium
9/16/2022
Pharvaris presented data supporting the development program for PHA121 at the Bradykinin Symposium 2022 in Berlin.
-
Pharvaris Reports Second Quarter 2022 Financial Results and Provides Business Update
9/12/2022
Pharvaris reported financial results for the second quarter ended June 30, 2022, and provided a business update.
-
The FDA is keeping busy as summer winds down, with approvals, Orphan Drug Designations and other actions. Here’s what the agency has been up to this week.
-
Pharvaris Announces FDA Clinical Hold on PHA121 Clinical Trials in the U.S.
8/22/2022
Pharvaris announced that the U.S. Food and Drug Administration verbally informed Pharvaris that, based on its review of nonclinical data, the agency is placing a clinical hold on the clinical trials of PHA121 in the U.S. under two Pharvaris Investigational New Drug applications for the treatment of HAE.
-
Pharvaris to Participate in H.C. Wainwright 1st Annual Hereditary Angioedema (HAE) Conference
7/14/2022
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema (HAE), today announced that management will participate in a fireside chat at the H.C. Wainwright 1st Annual Hereditary Angioedema (HAE) Conference taking place virtually on July 20, 2022.
-
Enavate Sciences Appoints Industry Veteran Robert Glassman as Executive Vice President, Search & Evaluation
7/11/2022
Enavate Sciences , a platform launched by Patient Square Capital to support transformative therapeutic companies, announced today the appointment of Robert Glassman, M.D., as Executive Vice President, Search & Evaluation.
-
Pharvaris to Host Virtual Expert Perspectives on HAE: Unmet Needs and Therapeutic Options Webinar on July 13
7/6/2022
Pharvaris today announced that it will host a virtual webinar, titled Expert Perspectives on HAE: Unmet Needs and Therapeutic Options on Wednesday, July 13, 2022, at 10:00 a.m. ET/16:00 CET.
-
Pharvaris Announces Annual Meeting of Shareholders - June 14, 2022
6/14/2022
Pharvaris announced the annual general meeting of shareholders will take place on Wednesday, June 29, 2022, at 16:00 CEST.
-
Pharvaris Participates in the Kinin 2022 ConferencePharvaris’ tailored drug development approach to enable treatment of people living with all types of hereditary angioedema (HAE) presented at satellite symposium
6/7/2022
Pharvaris today announced the presentation of its development program at the Kinin 2022 Conference, to be held June 5-8, 2022, in Annecy, France.
-
Life sciences and biopharma companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Pharvaris Appoints Joan Schmidt, J.D., as Chief Legal Officer
5/11/2022
Pharvaris’ executive team further strengthened by Ms. Schmidt’s deep international experience and biopharmaceutical industry tenure.
-
Pharvaris Reports First Quarter 2022 Financial Results and Provides Business Highlights
5/11/2022
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema (HAE), today reported financial results for the first quarter ended March 31, 2022, and provided an update on recent business highlights.
-
Pharvaris to Participate in BofA Securities 2022 Healthcare Conference
5/5/2022
Pharvaris announced that management will present at the BofA Securities 2022 Healthcare Conference taking place in Las Vegas, NV from May 10 – 12, 2022.
-
Dutch biotech Xinvento raises seed round to develop a treatment for the rare disease Congenital Hyperinsulinism
4/21/2022
Xinvento, a biotech company aiming to improve the lives of those with Congenital Hyperinsulinism, announces the completion of a seed funding round.
-
Pharvaris to Participate in Upcoming April 2022 Investor Conferences
4/6/2022
Pharvaris, a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema, announced that management will participate in two upcoming investor conferences in April.
-
Pharvaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights
3/29/2022
Pharvaris today reported financial results for the fourth quarter and year ended December 31, 2021 and provided recent business highlights.
-
Pharvaris Announces Preclinical Pharmacological Data for Small Molecule PHA121 Published in International Immunopharmacology
3/22/2022
Pharvaris (Nasdaq: PHVS), has published pharmacological data for the novel small molecule bradykinin (BK) B2-receptor antagonist PHA121 (PHA-022121) and its active metabolite PHA-022484, in a recent open-access article in International Immunopharmacology and will be published in the April 2022 issue of the journal.
-
Pharvaris to Participate in Upcoming March 2022 Investor Conferences
3/3/2022
Pharvaris announced that management will participate in three upcoming investor conferences in March.
-
Pharvaris to Participate in 11th Annual SVB Leerink Global Healthcare Conference
2/9/2022
Pharvaris announced that management will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference taking place virtually from February 14–18, 2022.
-
What makes a candidate attractive? For Deschoolmeester, three critical elements stand out: pragmatism, creativity and collaboration.